Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma

Inclusion Criteria:

- Eligible patients must be at least 18 years of age with a diagnosis of metastatic
kidney cancer.

- The patient's kidney cancer must have gotten worse during/after previous
cytokine-based therapy was given.

- Any side effects from prior therapy must have subsided, and blood and urine tests
must show adequate bone marrow, liver, and kidney function

Exclusion Criteria:

- Prior treatment with any systemic therapy other than 1 prior cytokine-based treatment
regimen;

- Prior surgical resection of or irradiation to the only site of measurable disease;

- Ongoing severe hematuria;

- Other active second malignancy;

- Cardiovascular diseases or conditions within the last 12 months;

- Known brain metastases;

- Known HIV-positive or AIDS-related illness;

- Pregnant or breast-feeding women;

- Current participation in other clinical trials;

- Other severe acute or chronic medical conditions.